Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 8 years, with Q4 2025 value amounting to $104.0 million.

  • Agios Pharmaceuticals' Total Non-Current Liabilities fell 1428.94% to $104.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $104.0 million, marking a year-over-year decrease of 1428.94%. This contributed to the annual value of $104.0 million for FY2025, which is 1428.94% down from last year.
  • According to the latest figures from Q4 2025, Agios Pharmaceuticals' Total Non-Current Liabilities is $104.0 million, which was down 1428.94% from $101.3 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $164.0 million in Q3 2024 and a low of $88.1 million during Q1 2025
  • Over the past 5 years, Agios Pharmaceuticals' median Total Non-Current Liabilities value was $119.5 million (recorded in 2023), while the average stood at $119.4 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 3748.73% in 2024, and later crashed by 3822.8% in 2025.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Total Non-Current Liabilities stood at $145.8 million in 2021, then dropped by 7.64% to $134.6 million in 2022, then fell by 7.19% to $124.9 million in 2023, then decreased by 2.87% to $121.4 million in 2024, then dropped by 14.29% to $104.0 million in 2025.
  • Its last three reported values are $104.0 million in Q4 2025, $101.3 million for Q3 2025, and $101.6 million during Q2 2025.